Cargando…

Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study

BACKGROUND: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants. METHODS: We analyzed an Italian database of young children referred to emergency de...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestri, Michela, Marando, Francesca, Costanzo, Anna Maria, di Luzio Paparatti, Umberto, Rossi, Giovanni A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845497/
https://www.ncbi.nlm.nih.gov/pubmed/27112952
http://dx.doi.org/10.1186/s13052-016-0252-9
_version_ 1782428958813323264
author Silvestri, Michela
Marando, Francesca
Costanzo, Anna Maria
di Luzio Paparatti, Umberto
Rossi, Giovanni A.
author_facet Silvestri, Michela
Marando, Francesca
Costanzo, Anna Maria
di Luzio Paparatti, Umberto
Rossi, Giovanni A.
author_sort Silvestri, Michela
collection PubMed
description BACKGROUND: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants. METHODS: We analyzed an Italian database of young children referred to emergency departments for acute lower respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental characteristics and the RSV positivity (RSV(+)) in hospitalized and not-hospitalized patients were compared. In the data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA). RESULTS: Out of the 100 children evaluated, 68 were infants (≤12 month-age): 7.5 and 20.6 % were in the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from 4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV(+) was also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the >12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29 wGA group with a low RSV(+) frequency (<29 %) in all wGA groups. In the ≤12 month-age group, 41 infants were evaluated with a ≤6 month-age and 27 with a >6–12 month-age. A positive hospitalized-to-not-hospitalized ratios was found in all wGA groups in ≤6 month-age infants, despite a low RSV(+) frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a <29 and 29- < 32 wGA were hospitalized with a relatively high RSV(+) frequency whilst the 32- < 35 wGA group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV(+) frequency. CONCLUSIONS: The hospitalized-to-not-hospitalized ratios and RSV(+) frequency in the first 12 months of age in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection, most notably in the <32 wGA category.
format Online
Article
Text
id pubmed-4845497
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48454972016-04-27 Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study Silvestri, Michela Marando, Francesca Costanzo, Anna Maria di Luzio Paparatti, Umberto Rossi, Giovanni A. Ital J Pediatr Research BACKGROUND: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants. METHODS: We analyzed an Italian database of young children referred to emergency departments for acute lower respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental characteristics and the RSV positivity (RSV(+)) in hospitalized and not-hospitalized patients were compared. In the data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA). RESULTS: Out of the 100 children evaluated, 68 were infants (≤12 month-age): 7.5 and 20.6 % were in the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from 4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV(+) was also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the >12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29 wGA group with a low RSV(+) frequency (<29 %) in all wGA groups. In the ≤12 month-age group, 41 infants were evaluated with a ≤6 month-age and 27 with a >6–12 month-age. A positive hospitalized-to-not-hospitalized ratios was found in all wGA groups in ≤6 month-age infants, despite a low RSV(+) frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a <29 and 29- < 32 wGA were hospitalized with a relatively high RSV(+) frequency whilst the 32- < 35 wGA group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV(+) frequency. CONCLUSIONS: The hospitalized-to-not-hospitalized ratios and RSV(+) frequency in the first 12 months of age in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection, most notably in the <32 wGA category. BioMed Central 2016-04-26 /pmc/articles/PMC4845497/ /pubmed/27112952 http://dx.doi.org/10.1186/s13052-016-0252-9 Text en © Silvestri et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Silvestri, Michela
Marando, Francesca
Costanzo, Anna Maria
di Luzio Paparatti, Umberto
Rossi, Giovanni A.
Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
title Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
title_full Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
title_fullStr Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
title_full_unstemmed Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
title_short Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
title_sort respiratory syncytial virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in italy: a retrospective analysis from the osservatorio study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845497/
https://www.ncbi.nlm.nih.gov/pubmed/27112952
http://dx.doi.org/10.1186/s13052-016-0252-9
work_keys_str_mv AT silvestrimichela respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy
AT marandofrancesca respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy
AT costanzoannamaria respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy
AT diluziopaparattiumberto respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy
AT rossigiovannia respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy